Company profileMixed portfolio#812 of 1,318 in Pakistan✓ No DRAP alerts

FARMIGEA

Mixed portfolio · 13 pharmaceutical brands of 9 registrations

Ranked #13 of 32 companies in Antiinflammatory Agents And Antiinfectives In Combination

9 registered products 13 pharmaceutical brands 16 distinct molecules 0 DRAP alerts
Part of this company's portfolio (“Eye”) is registered under a broad DRAP category rather than distinct molecules, so the molecule count understates its true range.

Company overview

9
registered products
13
pharmaceutical brands
16
distinct molecules
6
therapeutic classes
0
DRAP alerts

FARMIGEA is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 9 product registrations across 16 distinct molecules. Its portfolio is concentrated in Antiinflammatory Agents And Antiinfectives In Combination and Anti-Infective, Ophthalmologicals. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Eye6 brands
Tobramycin2 brands
Diclofenac1 brand
Neomycin1 brand
Carbachol1 brand

Therapeutic classes

Antiinflammatory Agents And Antiinfectives In Combination · 3Anti-Infective, Ophthalmologicals · 2Mydriatics And Cycloplegics · 1Antiglaucoma Preparations And Miotics · 1Decongestants And Antiallergics · 1Antiinflammatory Agents, Corticosteroids · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for FARMIGEA

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.